// App-Quantinova.ai

TCT-36 : One-year Clinical Outcomes of Diabetic Patients Treated With Everolimus-Eluting Bioresorbable Vascular Scaffolds: A Pooled Analysis From the ABSORB Cohort B and the ABSORB EXTEND Trials.

Researchers

Presenter

  • Takashi Muramatsu

Principal Investigators

  • Yoshinobu Onuma

  • Robert J. Van Geuns

  • Bernard Chevalier

  • Tejas M. Patel

  • Ashok Seth

  • Roberto Diletti

  • Hector M. Garcia-Garcia

  • Cecile Dorange

  • Susan Veldhof

Medical Centers

  • Thoraxcenter, Erasmus Medical Center, Rotterdam, Rotterdam, Netherlands

  • New Delhi, India

  • University of Milan, Milan, Italy

  • ICPS, Massy, France

  • Thoraxcenter, Rotterdam, The Netherlands, Rotterdam, Netherlands

  • St Vincents Hospital, University of Melbourne, Melbourne, Victoria, Australia

  • Erasmus MC, Rotterdam, Netherlands

  • Thoraxcenter, Erasmus MC, Rotterdam, Netherlands

  • Thoraxcenter, Rotterdam, Netherlands

  • Abbott Vascular International BVBA, Diegem, Belgium

Locations

  • Italy

  • Netherlands

  • Australia

  • France

  • India

  • Belgium

Companies

  • Abbott

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Myocardial infarction

  • Hypertension

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Everolimus

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved